Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
3,5-diiodothyronine is a naturally occurring thyroid hormone and a metabolite of triiodothyronine (T3). It acts as an active thyroid hormone analog and is found in small amounts in the human body. Research indicates that it can increase resting metabolic rate and oxygen consumption by directly stimulating mitochondrial activity. In animal studies (notably rats), administration of 3,5-diiodothyronine has been shown to reduce body mass gain and fat storage while increasing energy expenditure. Mechanistically, it acts as an alternative ligand for the thyroid hormone receptor beta and stimulates hepatic lipid catabolism through mechanisms distinct from T3. It also suppresses the hypothalamic-pituitary-thyroid axis by reducing serum levels of TSH (thyroid-stimulating hormone), thyroxine (T4), and triiodothyronine (T3). While some research suggests potential applications for obesity or hyperlipidemia due to its metabolic effects, there is no robust clinical evidence supporting its use in humans for these indications[1][4][5][8].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on 3,5-diiodothyronine.